TRPC4 and synovial sarcoma: Based on the result of our study, we propose that heteromeric TRPC4/C1 is a primary target of EA for a potent anti-human synovial sarcoma cell effect mediated via Na+ loading caused by sustained channel activation coupled with insufficient compensation by Na+/K+-ATPase.